The incidence of oesophageal cancer, in particular adenocarcinoma, has markedly
increased over the last four decades with adenocarcinoma becoming the dominant subtype …

Esophageal cancer (EC) is an aggressive malignancy with an increasing incidence and a
poor prognosis. EC is histologically divided into two major categories: adenocarcinoma …

Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-
oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the …

Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide.
Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and …

Background Clinical benefit of neoadjuvant immunotherapy in resectable esophageal
squamous cell carcinoma (ESCC). remains unclear. This study evaluated the efficacy and …

Background Both perioperative chemotherapy and postoperative chemoradiotherapy
improve survival in patients with resectable gastric cancer from Europe and North America …

PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical
decision making for patients with locally advanced esophageal cancer. METHODS ASCO …

Background The standard neoadjuvant treatments in patients with esophageal squamous
cell carcinoma (ESCC) still have either poor safety or efficacy. Better therapies are needed …

Background Esophageal cancer is regarded as an orphan disease in the United States;
however, it represents a significant global problem and is the sixth most common cause of …